摘要
目的探讨MDR1基因表达产物P-糖蛋白(P-gp)在非小细胞肺癌中的表达水平及其临床意义。方法采用免疫组织化学标记链亲和素-生物素法检测126例非小细胞肺癌标本中P-gp的表达。结果(1)P-gp总的阳性表达率为56.3%(71/126);(2)腺癌与鳞癌之间,鳞癌与腺鳞癌之间P-gp的表达阳性率无显著差异(P>0.05),但腺鳞癌P-gp的阳性表达率高于腺癌(P<0.05);(3)P-gp的表达与性别、年龄、肿瘤生长部位、病理分期及是否伴有淋巴结转移无关。结论P-gp在非小细胞肺癌中有较高的阳性表达率,且与病理类型有一定关系,提示在非小细胞肺癌尤其是P-gp高度表达类型肺癌的化疗中,应重视P-gp介导的多药耐药性。
Objective To explore the expression level and its clinical significance of MDR 1 gene product, the P glycoprotein (P gp) in non small cell lung cancer. Methods Results (1) 71 (56.3%) out of the 126 NSCLC were positive for the P gp expression. (2) No significant difference was found between adenocarcinoma and squamous carcinoma of NSCLC in P gp expression ( P>0.05) , as same as the squamous carcinoma and adenosquamous carcinoma. P gp positive expression of adenosquamous carcinoma was significantly higher than that of the adenocarcinoma ( P <0.05). (3) The positive expression of P gp were not correlated to the sexes, ages, location of tumor occuring, stages of the tumor, and with or without lymph node metastasis ( P> 0.05) . Conclusion The positive expression of P gp is higher in NSCLC and correlated to the pathological patterns in some degree. It is suggested that multidrug resistance induced by overexpression of P gp should be considered for the NSCLC undertaking chemotherapy, especially for the pathological patterns with higher P gp positive expression.
出处
《中国胸心血管外科临床杂志》
CAS
1997年第2期73-75,共3页
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery